HAE Q3 Earnings In Line, '25 Sales View Cut, Stock Up in Aftermarket
Portfolio Pulse from
Haemonetics reported its third-quarter fiscal 2025 earnings, which were in line with expectations. The company showed meaningful earnings growth and margin expansion, reflecting the positive effects of its long-range plan. Despite cutting its 2025 sales outlook, the stock rose in aftermarket trading.
February 07, 2025 | 3:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Haemonetics' Q3 fiscal 2025 earnings were in line with expectations, showing strong earnings growth and margin expansion. The company cut its 2025 sales outlook, but the stock rose in aftermarket trading.
The company's earnings met expectations and showed strong growth, which is positive for the stock. Although the sales outlook was cut, the market reacted positively, as evidenced by the stock's rise in aftermarket trading.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100